Glaucoma

LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens created by the company’s proprietary 3D printing technology.

Switching produced an additional 25% IOP reduction in mild-to-moderate OAG and OHT.

Findings from Mass Eye and Ear’s collaborative study provides new insights regarding gene expression and post-transcriptional gene regulation.

Oluwatosin U Smith, MD, urges consideration of the interaction between corneal and glaucomatous disease whenever treating glaucoma or corneal issues during the annual Glaucoma 360 meeting in San Francisco, California.

Optometry Times chats with Michael Chaglasian, OD, FAAO during this year's Glaucoma 360 meeting in San Francisco, California.

Pairing the patient with the right therapy can yield dramatic results.

Robert L Stamper, MD, raises the question of physician liability for allowing the patient to drive.

Shan C. Lin, MD, discusses combined minimally invasive glaucoma surgery and its impact on achieving improved intraocular pressure efficacy.

In a news release, the FDA noted these are copycat eye drop products that consumers can easily mistake for Bausch + Lomb’s Lumify brand eye drops, an over-the-counter product approved for redness relief.

Retinal imaging and genetics data was used to predict future disease risk in a recent study.

The new contact lenses contain micro-sensors which monitor changes in IOP over a period of several hours, sending the data collected wirelessly so it can be analyzed by an eye care provider and a diagnosis given.

Recent research gives clinicians another reason to encourage cessation.

The 2024 EnVision Summit will feature a brand-new Optometry Program, co-chaired by Danica Marrelli, OD, FAAO, AAO Dipl, and Cecelia Koetting, OD, FAAO, DipABO.

The eye care company and nonprofit organization are teaming up to provide educational resources, patient stories, and a fundraising challenge to help find a cure for glaucoma.

Available information includes a new promotional toolkit for The Glaucoma Community, glaucoma patient testimonial, and medical expert interview videos.

iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has received FDA approval following a new drug application (NDA) submission.

Earlier this year, Aurion’s cell therapy received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for the management of bullous keratopathy, marking the first regulatory approval in the world for an allogeneic cell therapy to manage corneal endothelial disease.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

Myopia as a glaucoma risk factor, and high myopia as a potential glaucoma mimicker, can be quite the clinical headache

As new treatment options continue to enter the glaucoma space, clinicians can provide the best care to each individual patient.

At AAOpt, Nate Lighthizer, OD, presents a variety of lectures and workshops on lasers and their use in optometry.

Gleb Sukhovolskiy discusses his 2023 AAOpt presentation, "Optometrist’s Guide to MIGS and the Continuing Evolution of Glaucoma Treatment."

At AAOpt, Justin Schweitzer, OD, FAAO, and Selina McGee, OD, FAAO, Dipl ABO, discuss the intersection of dry eye and glaucoma.